1933 Industries Inc. (TGIFF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

1933 Industries Inc. (TGIFF) Healthcare & Pipeline Overview

1933 Industries Inc. is a Canadian cannabis enterprise engaged in the cultivation and production of medical and recreational marijuana across North America. The company diversifies its offerings with a comprehensive portfolio of CBD-infused products, including personal care items and ingestibles, marketed under distinct brands and distributed through a multi-channel strategy.

What Is the Investment Thesis for TGIFF?

1933 Industries Inc. operates within the expanding cannabis and CBD markets, leveraging its cultivation capabilities and diverse product portfolio. The company's P/E ratio of 10.75 and a profit margin of 2.8% indicate a profitable operation, albeit with a relatively low margin in a capital-intensive industry. A key value driver is its multi-channel distribution network for CBD products, encompassing dispensaries, retail outlets, and e-commerce, which enhances market penetration and brand visibility across its Canna Hemp lines. Growth catalysts include potential further legalization or regulatory easing in key U.S. states, which could expand its addressable market for both THC and CBD products. The company's focus on both medical and recreational segments in the US and Canada provides diversification. However, its operation in the OTC Other tier presents risks related to liquidity and disclosure, as highlighted by its Beta of 1.60, indicating higher volatility compared to the broader market. Sustained market share expansion amidst increasing competition is crucial for long-term value creation.

Based on FMP financials and quantitative analysis

TGIFF Key Highlights

Market Capitalization: $0.00 billion, reflecting its current valuation as a micro-cap entity.

• Price-to-Earnings (P/E) Ratio: 10.75, indicating profitability relative to its share price.
• Profit Margin: 2.8%, demonstrating the company's net income as a percentage of revenue.
• Gross Margin: 13.6%, representing the percentage of revenue left after deducting the cost of goods sold.
• Beta: 1.60, suggesting the stock is 60% more volatile than the overall market.

Who Are TGIFF's Competitors?

TGIFF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TGIFF's Key Strengths?

Diversified product portfolio including both THC and a wide range of CBD-infused items.

• Established brand presence with multiple Canna Hemp lines.
• Multi-channel distribution strategy for CBD products, including e-commerce.
• Cultivation and production capabilities in both the US and Canada.

What Are TGIFF's Weaknesses?

Operating in the OTC Other tier, implying higher risk and potentially lower liquidity.

• Relatively low profit margin of 2.8% in a competitive industry.
• High stock volatility with a Beta of 1.60.
• Market capitalization of $3.07M indicates a micro-cap status, potentially limiting institutional interest.

What Could Drive TGIFF Stock Higher?

TGIFF catalyst: Potential federal or state-level regulatory reforms in the U.S. that could expand market access for cannabis products.

• Expansion of the company's multi-channel distribution network for its Canna Hemp CBD brands, increasing market penetration.
• Introduction of new CBD or THC product formulations and innovations to capture emerging consumer preferences.
• Strategic partnerships or collaborations that could enhance cultivation capabilities or market reach.

What Are the Key Risks for TGIFF?

Financial-distress signal — its Altman Z-Score of -8.17 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-11.6%) — the business is not currently generating profit on shareholder capital.
• Operating in the OTC Other tier, which carries inherent risks of lower liquidity and less stringent disclosure requirements.
• Intense competition within the fragmented cannabis and CBD markets, potentially leading to pricing pressures and market share erosion.
• Adverse changes in cannabis regulatory frameworks in the U.S. or Canada, impacting cultivation, production, or distribution.
• High stock volatility, indicated by a Beta of 1.60, exposing investors to significant price fluctuations.
• Challenges in maintaining regulatory compliance across multiple jurisdictions with evolving cannabis laws.

What Are the Growth Opportunities for TGIFF?

• Expansion of CBD Product Lines and Market Reach: 1933 Industries can significantly grow by further expanding its comprehensive portfolio of CBD-infused products, including personal care items, ingestibles, and health supplements. The global CBD market is projected to continue its robust growth, with estimates often placing its value in the tens of billions of dollars by the late 2020s. By introducing new formulations, targeting specific wellness needs, and leveraging its existing Canna Hemp brands, the company can capture a larger share of this expanding market. Enhancing its e-commerce platform and securing additional retail partnerships will be crucial for broader distribution.
• Increased Cannabis Legalization in the United States: The ongoing trend of cannabis legalization across more U.S. states, both for medical and recreational use, presents a substantial growth opportunity. As federal or state-level regulations evolve, 1933 Industries, with its existing cultivation and production capabilities in the U.S., can strategically enter newly opened markets. This expansion would significantly increase its addressable market for THC concentrates and conventional cannabis flowers. The U.S. cannabis market is estimated to reach over $40 billion by 2026, offering immense potential for companies positioned to capitalize on regulatory shifts.
• Development of Branded THC Products: While the company currently supplies conventional cannabis flowers and concentrates, there is an opportunity to develop and market branded THC products similar to its successful Canna Hemp CBD lines. Establishing strong, recognizable THC brands could command higher margins and foster greater consumer loyalty in competitive recreational markets. This strategy would involve investing in product differentiation, packaging, and targeted marketing campaigns, leveraging the company's existing cultivation infrastructure to ensure consistent quality and supply.
• Strategic Partnerships and Acquisitions: Pursuing strategic partnerships with established distributors, retailers, or even smaller, innovative cannabis companies could accelerate market penetration and product diversification. Acquisitions of complementary businesses, particularly those with strong regional presence or specialized product lines, could enhance 1933 Industries' market share and operational efficiencies. Such inorganic growth strategies could provide access to new intellectual property, cultivation techniques, or distribution channels, allowing the company to scale more rapidly within the fragmented cannabis industry.
• Refinement of Cultivation Techniques and Yield Optimization: Continuous investment in advanced cultivation technologies and practices can lead to improved yields, higher potency, and reduced production costs. Optimizing its cultivation facilities in the U.S. and Canada through environmental controls, genetics research, and efficient harvesting methods can enhance profitability. This focus on operational excellence ensures a consistent supply of high-quality raw materials for both its THC and CBD product lines, strengthening its competitive position and enabling better pricing strategies in a commoditized market segment.

What Threats Does TGIFF Face?

• Intensifying competition from larger, better-capitalized cannabis companies.
• Evolving and unpredictable regulatory landscape in the cannabis industry.
• Potential for product commoditization and pricing pressures.
• Challenges associated with operating on the OTC market, including investor perception and capital raising.

What Are TGIFF's Competitive Advantages?

• Established Brand Portfolio: A suite of recognized CBD brands (Canna Hemp, Canna Hemp X, Canna Hemp PLUS, Canna Hemp HEMP, Canna Fused) provides market recognition and consumer trust.
• Multi-Channel Distribution Network: Access to retail dispensaries, general retail outlets, and a dedicated e-commerce platform ensures broad market penetration for CBD products.
• Integrated Operations: Engagement in cultivation, production, and distribution across both THC and CBD segments allows for greater control over the supply chain and product quality.
• Geographic Diversification: Operations in both the United States and Canada mitigate risks associated with single-market regulatory changes and expand the addressable market.

What Does TGIFF Do?

1933 Industries Inc., headquartered in Vancouver, Canada, operates as a diversified cannabis enterprise with a focus on both the medical and recreational marijuana markets across the United States and Canada. Established initially as Friday Night Inc., the company underwent a strategic rebranding to 1933 Industries Inc. in September 2018, signaling its evolving market presence and strategic direction within the rapidly expanding cannabis sector. The company's core operations encompass the cultivation and production of cannabis, serving a broad spectrum of consumer needs from traditional flower to advanced concentrates. Beyond its cultivation activities, 1933 Industries has developed a robust portfolio of cannabidiol (CBD)-infused products, which represents a significant segment of its business model. This extensive product line is designed to cater to various consumer preferences and includes personal care items such as lotions and lip balms, ingestibles like edibles, hemp seed oils, and drink additives, as well as health and wellness supplements in the form of tinctures and capsules. The company also offers specialized products like vaping solutions and baking ingredients, alongside tetrahydrocannabinol (THC) concentrates. These CBD offerings are strategically marketed under several distinct and recognized brands, including Canna Hemp, Canna Hemp X, Canna Hemp PLUS, Canna Hemp HEMP, and Canna Fused, allowing the company to target specific consumer demographics and product niches. The distribution strategy for its CBD-infused products is multi-channel, encompassing traditional retail dispensaries, other general retail outlets, and a dedicated e-commerce platform, ensuring broad market reach. This comprehensive approach, from cultivation to branded product development and diverse distribution, positions 1933 Industries Inc. as a multifaceted player in the North American cannabis and CBD markets.

What Products and Services Does TGIFF Offer?

• Cultivates and produces medical marijuana in the United States and Canada.
• Cultivates and produces recreational marijuana in the United States and Canada.
• Manufactures a comprehensive array of cannabidiol (CBD)-infused products.
• Offers personal care items like lotions and lip balms under CBD brands.
• Provides ingestible CBD products such as edibles, hemp seed oils, and drink additives.
• Sells health and wellness CBD supplements including tinctures and capsules.
• Supplies vaping solutions, baking ingredients, and tetrahydrocannabinol (THC) concentrates.
• Markets CBD lines under distinct brands: Canna Hemp, Canna Hemp X, Canna Hemp PLUS, Canna Hemp HEMP, and Canna Fused.

How Does TGIFF Make Money?

• Generates revenue through the cultivation and direct sale of medical and recreational cannabis flower and concentrates.
• Earns income from the manufacturing and multi-channel distribution of a diverse range of branded CBD-infused products.
• Utilizes a multi-channel sales strategy, including retail dispensaries, other retail outlets, and an e-commerce platform, to maximize product reach.
• Focuses on brand development and marketing for its CBD lines to build consumer loyalty and differentiate products in a competitive market.

What Industry Does TGIFF Operate In?

1933 Industries Inc. operates within the dynamic and rapidly evolving Drug Manufacturers - Specialty & Generic industry, specifically focusing on the cannabis and CBD sub-sectors. The broader cannabis market is characterized by ongoing regulatory changes, particularly in North America, where increasing state-level legalization for medical and recreational use continues to drive market expansion. This environment fosters both significant growth opportunities and intense competition from established players and new entrants. 1933 Industries positions itself as a vertically integrated player, engaged in cultivation, production, and multi-channel distribution of both THC and CBD products. The company's diverse brand portfolio, including Canna Hemp, allows it to capture various consumer segments within the health and wellness, personal care, and recreational cannabis markets. Its presence in both the US and Canada provides geographic diversification, navigating differing regulatory frameworks to capitalize on market trends.

Who Are TGIFF's Key Customers?

• Medical cannabis patients seeking therapeutic benefits.
• Recreational cannabis consumers in legal markets.
• Consumers interested in health and wellness products, specifically CBD-infused items.
• Retail dispensaries and other retail outlets that stock cannabis and CBD products.
• E-commerce customers purchasing directly from the company's online platform.

Company Profile

1933 Industries Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO Brian Farrell. TGIFF has traded publicly since 2013.

1933 Industries Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -8.17 places it in the distress zone, a signal of elevated financial risk.

Return on equity for 1933 Industries Inc. stands at -11.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.0%, showing how much profit it generates from its asset base. TGIFF trades at a trailing price-to-earnings ratio of 11.12, below the Healthcare sector average of ~23x. Its free cash flow yield is 36.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.11 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 9.0%, the inverse of the P/E and a quick read on earnings relative to price.

TGIFF Valuation & Market Position

With a $3.07M market cap, 1933 Industries Inc. sits in the micro-cap segment of the market. Relative to its peer group, TGIFF's quantitative score of 36/100 is below the peer average of 62/100.

Wall Street analysts project 1933 Industries Inc. revenue of about $13.7M for fiscal 2026, with EPS near $-0.05.

TGIFF Financials

TGIFF Latest News

No recent news available for TGIFF.

TGIFF Analyst Consensus

TGIFF MoonshotScore

Common Questions About TGIFF (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources